

What's on the horizon for the treatment of GI tumours in 2019?



Prof. Eric Van Cutsem, MD, PhD
Head of Digestive Oncology at the
University Hospitals, Leuven,
Belgium.

Disclaimer

Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions.

The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use.

No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities.

touchIME accepts no responsibility for errors or omissions.

Novel treatment strategies for GI tumours

- During the past 10–15 years, **novel tumour immunotherapeutic approaches** have revolutionised GI cancer treatment

Immune checkpoint inhibitors

- Such as PD-1/PD-L1 or CTLA-4, have demonstrated innovative progression in mCRC and gastric cancers^{1,2}

PARP inhibitors

- Have shown potential benefit in patients with pancreatic cancer and BRCA1/2 mutation³
- When used in combination, may enhance the effect of other therapies⁴

- The use of a **biomarker-based strategy** will help select patients for an individualised therapy approach²

CTLA-4, T lymphocyte antigen 4; GI, gastrointestinal; mCRC, metastatic colorectal cancer; PARP, poly(adenosine diphosphate-ribose) polymerase; PD-1/PD-L1; programmed cell death protein 1/programmed cell death ligand 1.

1. Sanz-Garcia E, et al. *Ann Oncol*. 2017;**28**:2648–2657; 2. Seliger B. *Front Immunol*. 2019;**10**:999. Published online 2019 May 22. doi: 10.3389/fimmu.2019.00999;

3. Golan T, et al. *N Engl J Med*. 2019;**381**:317–327; 4. Guo X, et al. *Cancer Manag Res*. 2018;**10**: 2553–2562.

Treatment choice based on individual patient and disease characteristics

- Knowledge of the patient's genomic, biological, and immunological condition will contribute to selecting the most curative treatment

For example:

Responses to BRAF monotherapy treatment are limited in patients with mCRC and the *BRAF* mutation (V600E)

Gene expression profiling establishes mCRC molecular classification to help inform treatment



Doublet and triplet combinations offer a potential strategy to overcome resistance in BRAF-mt CRC¹

Doublet and triplet combinations of BRAF inhibitors with antibodies targeting EGFR, MEK and/or PI3K inhibitors have been tested in BRAF-mt CRC with encouraging results

- However, the low prevalence of the BRAF mutation means more large collaborative studies are needed to improve survival in these patients¹


The sequencing of therapies is challenging



Improvements in **biomarker-based patient selection**, the number of lines of therapy administered and sequencing are factors that have improved treatment outcomes for patients with mCRC



Uncertainty remains as to which is the best combination to use for patients stratified according to the molecular profile of their disease



In a rapidly evolving field, as more treatment options become available, sequencing will become even more important and challenging

ESMO guidelines provide evidence-based guidance on first and subsequent lines of treatment


**CLINICAL PRACTICE
GUIDELINES**

An ESMO Product



Advances in precision oncology

Aim to improve treatment options and patient outcomes



Latest updates from ESMO 2019

- New data in GI cancer including:

Selective
combination therapy
for patients with
BRAF^{V600E} mCRC

Data for first line
treatment with
checkpoint inhibitors
in gastric cancer

PARP inhibitors in
pancreatic cancer

IDH inhibition in
metastatic biliary
tract cancer